SBWire

Ebola Viral Infections - Pipeline Review, H1 2014

Bioheart, Inc. - Product Pipeline Review - 2014

Recently published research from Global Markets Direct, "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2014", is now available at Fast Market Research

T-Cell Lymphomas - Pipeline Review, H1 2014

Renal Cell Carcinoma - Pipeline Review, H1 2014

Lyme Disease - Pipeline Review, H1 2014

Otitis Media - Pipeline Review, H1 2014

RedHill Biopharma Ltd. - Product Pipeline Review - 2014

GlobalData's clinical trial report, "Hyperglycemia Global Clinical Trials Review, H1, 2014" provides data on the Hyperglycemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperglycemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hyperglycemia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Selvita S.A - Product Pipeline Review - 2014

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014

Autism - Pipeline Review, H1 2014

Non-Small Cell Lung Cancer - Pipeline Review, H1 2014

Inflammatory Bowel Disease - Pipeline Review, H1 2014

Keloids - Pipeline Review, H1 2014

Lung Adenocarcinoma - Pipeline Review, H1 2014

Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2014

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

The Pneumonia Partnering 2009-2014 report provides understanding and access to the pneumonia partnering deals and agreements entered into by the worlds leading healthcare companies.

Purdue Pharma L.P. - Product Pipeline Review - 2014

The Dialysis Partnering 2009-2014 provides understanding and access to the dialysis partnering deals and agreements entered into by the worlds leading healthcare companies.

Wounds - Pipeline Review, H1 2014

Obesity - Pipeline Review, H1 2014

Rabies - Pipeline Review, H1 2014